|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1201 Pennsylvania Avenue, NW |
Address2 | Suite 800 |
| City | Washington |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 41454-2676
|
||||||||
|
6. House ID# 307710185
|
||||||||
| TYPE OF REPORT | 8. Year | 2024 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Isabella Quinn |
Date | 7/19/2024 5:04:20 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; Medicare Part D; drug importation; and drug shortages. Drug pricing proposals. Medicare rebate reform, the 340B program, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). PASTEUR Act. Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Pharmacy benefit manager reform proposals. Public Law 118-47.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Susan |
Hirschmann |
|
|
|
Karina |
Lynch |
|
Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov. Affairs |
|
Melinda |
Maxfield |
|
|
|
Matthew |
Hoekstra |
|
|
|
Christopher |
Wilcox |
|
Regional Staff Asst & Staff Asst, Sen. Moynihan; LA, Leg Counsel, LD & Counsel, Rep. Arcuri; LD & Counsel, Rep. Demings |
|
Jeanne |
Haggerty |
|
Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member |
|
Alec |
Aramanda |
|
Prof Staff, House Cmtee on E&C; Dir Ofc of Legislation & Dir Stakeholder Engagement, Centers for Medicare & Medicaid Services; Deputy Assistant Secretary for Health Policy, Department of Health & Human Services; Domestic Policy Advisor, |
|
Alec |
Aramanda |
|
Deputy Legislative Director, Leg Asst, Sen. Cruz; Leg Asst, Sen. DeMint.
|
|
Kurt |
Schrader |
|
Former member of Congress. |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Tax issues affecting the pharmaceutical industry including international tax. Vaccine excise tax issues and VICP.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Susan |
Hirschmann |
|
|
|
Karina |
Lynch |
|
Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov. Affairs |
|
Christopher |
Hatcher |
|
Sch. C, Treasury; Associate Staff, House Rules Committee; LD, Rep. Scott McInnis |
|
Matthew |
Hoekstra |
|
|
|
Christopher |
Wilcox |
|
Regional Staff Asst & Staff Asst, Sen. Moynihan; LA, Leg Counsel, LD & Counsel, Rep. Arcuri; LD & Counsel, Rep. Demings |
|
Jeanne |
Haggerty |
|
Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member |
|
Alec |
Aramanda |
|
Prof Staff, House Cmtee on E&C; Dir Ofc of Legislation & Dir Stakeholder Engagement, Centers for Medicare & Medicaid Services; Deputy Assistant Secretary for Health Policy, Department of Health & Human Services; Domestic Policy Advisor, |
|
Alec |
Aramanda |
|
Deputy Legislative Director, Leg Asst, Sen. Cruz; Leg Asst, Sen. DeMint. |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Medicare payment issues and Medicaid issues. Medicare Part D. Drug pricing proposals. Protecting Seniors Through Immunization Act. Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Pharmacy benefit manager reform proposals. Public Law 118-47.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Susan |
Hirschmann |
|
|
|
Karina |
Lynch |
|
Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov. Affairs |
|
Matthew |
Hoekstra |
|
|
|
Christopher |
Wilcox |
|
Regional Staff Asst & Staff Asst, Sen. Moynihan; LA, Leg Counsel, LD & Counsel, Rep. Arcuri; LD & Counsel, Rep. Demings |
|
Jeanne |
Haggerty |
|
Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member |
|
Alec |
Aramanda |
|
Prof Staff, House Cmtee on E&C; Dir Ofc of Legislation & Dir Stakeholder Engagement, Centers for Medicare & Medicaid Services; Deputy Assistant Secretary for Health Policy, Department of Health & Human Services; Domestic Policy Advisor, |
|
Alec |
Aramanda |
|
Deputy Legislative Director, Leg Asst, Sen. Cruz; Leg Asst, Sen. DeMint. |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Issues related to pharmaceutical manufacturing and development. Legislative proposals related to WTO TRIPS Waiver.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Susan |
Hirschmann |
|
|
|
Karina |
Lynch |
|
Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov. Affairs |
|
Christopher |
Hatcher |
|
Sch. C, Treasury; Associate Staff, House Rules Committee; LD, Rep. Scott McInnis |
|
Matthew |
Hoekstra |
|
|
|
Christopher |
Wilcox |
|
Regional Staff Asst & Staff Asst, Sen. Moynihan; LA, Leg Counsel, LD & Counsel, Rep. Arcuri; LD & Counsel, Rep. Demings |
|
Jeanne |
Haggerty |
|
Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member |
|
Alec |
Aramanda |
|
Prof Staff, House Cmtee on E&C; Dir Ofc of Legislation & Dir Stakeholder Engagement, Centers for Medicare & Medicaid Services; Deputy Assistant Secretary for Health Policy, Department of Health & Human Services; Domestic Policy Advisor, |
|
Alec |
Aramanda |
|
Deputy Legislative Director, Leg Asst, Sen. Cruz; Leg Asst, Sen. DeMint. |
|
Kurt |
Schrader |
|
Former member of Congress. |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Support for immunization access.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Susan |
Hirschmann |
|
|
|
Matthew |
Hoekstra |
|
|
|
Christopher |
Wilcox |
|
Regional Staff Asst & Staff Asst, Sen. Moynihan; LA, Leg Counsel, LD & Counsel, Rep. Arcuri; LD & Counsel, Rep. Demings |
|
Jeanne |
Haggerty |
|
Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member |
|
Alec |
Aramanda |
|
Prof Staff, House Cmtee on E&C; Dir Ofc of Legislation & Dir Stakeholder Engagement, Centers for Medicare & Medicaid Services; Deputy Assistant Secretary for Health Policy, Department of Health & Human Services; Domestic Policy Advisor, |
|
Alec |
Aramanda |
|
Deputy Legislative Director, Leg Asst, Sen. Cruz; Leg Asst, Sen. DeMint. |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
Issues related to pharmaceutical manufacturing and development.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Susan |
Hirschmann |
|
|
|
Karina |
Lynch |
|
Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov. Affairs |
|
Matthew |
Hoekstra |
|
|
|
Christopher |
Wilcox |
|
Regional Staff Asst & Staff Asst, Sen. Moynihan; LA, Leg Counsel, LD & Counsel, Rep. Arcuri; LD & Counsel, Rep. Demings |
|
Jeanne |
Haggerty |
|
Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member |
|
Alec |
Aramanda |
|
Prof Staff, House Cmtee on E&C; Dir Ofc of Legislation & Dir Stakeholder Engagement, Centers for Medicare & Medicaid Services; Deputy Assistant Secretary for Health Policy, Department of Health & Human Services; Domestic Policy Advisor, |
|
Alec |
Aramanda |
|
Deputy Legislative Director, Leg Asst, Sen. Cruz; Leg Asst, Sen. DeMint. |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |